Capecitabine is a type of chemotherapy drug. It's used to treat certain kinds of cancer, like colon cancer or breast cancer. It works by stopping cancer cells from growing. It's usually taken as pills.
Every report comes from a Lived member, sent anonymously.
Have you tried Xeloda (Capecitabine) for Colorectal Cancer?
Capecitabine, sold under the brand name Xeloda and as generic tablets, is a chemotherapy medicine taken by mouth. It is used for several cancers of the digestive tract and for breast cancer, often as one part of a larger treatment plan. In colorectal cancer, it is given after surgery for stage III colon cancer (cancer that has reached nearby lymph nodes) to lower the chance of the cancer coming back. It is combined with radiation around the time of surgery for locally advanced rectal cancer, and it treats colorectal cancer that has spread or cannot be removed. In a large trial after colon cancer surgery, capecitabine tablets prevented recurrence at least as well as intravenous (IV) fluorouracil with leucovorin, the older standard. In breast cancer, it treats advanced or metastatic disease, either on its own when the usual chemotherapy families (anthracyclines or taxanes) are not suitable, or together with docetaxel after earlier anthracycline chemotherapy has stopped working. It is also used with other cancer drugs for advanced stomach, esophageal and gastroesophageal junction cancers, including HER2-positive stomach cancer (a type driven by extra amounts of a growth-signal protein called HER2) alongside trastuzumab (Herceptin), and after surgery for pancreatic cancer together with gemcitabine. Because its role differs so much between these uses, the schedule, the number of cycles and the medicines given with it depend on the specific cancer and the goal of treatment.
Capecitabine is a prodrug: the tablet itself is inactive until the body converts it, in several steps, into fluorouracil (often called 5-FU), a long-established chemotherapy drug that is otherwise given by IV. Fluorouracil blocks an enzyme cells need to make one of the building blocks of DNA, and it also gets built into RNA by mistake, disrupting how cells make proteins. Cells that divide rapidly, such as cancer cells, are especially affected, so the drug slows or stops tumor growth. The same effect explains the typical side effects. The lining of the gut, the skin of the hands and feet, and the bone marrow that makes blood cells all renew themselves quickly, so they are the tissues most often irritated. An enzyme called DPD (dihydropyrimidine dehydrogenase) normally breaks down most of the fluorouracil in the body. Inherited variants in the DPYD gene, which carries the instructions for DPD, can leave the enzyme partly or completely inactive. People with low DPD activity are exposed to much more of the drug, which is why testing for these variants matters before treatment starts.
Capecitabine comes as 150 mg and 500 mg tablets taken twice a day, about 12 hours apart and at the same times each day. Swallow the tablets whole with water within 30 minutes after a meal. Do not chew, cut or crush them; dust from broken tablets has caused eye irritation, rash and stomach upset. Capecitabine is classed as a hazardous drug, so follow the pharmacy's handling and disposal instructions, and tell the care team if swallowing whole tablets is a problem. The dose is calculated from body size (body surface area, worked out from height and weight) and the specific treatment plan, so a single dose often combines both tablet strengths. The most common schedule is two weeks of tablets followed by one week off, repeated in three-week cycles. Other plans differ: some stomach cancer regimens take it every day of the cycle, pancreatic cancer treatment uses three weeks on and one week off, and doses are lower when it is given alongside radiation for rectal cancer. Follow the written calendar for the plan rather than a general rule. If a dose is missed or vomited, do not take an extra dose; take the next one at the usual time. People with moderately reduced kidney function receive a lower dose, and no safe dose has been set for severe kidney impairment.
The most common side effects are hand-foot syndrome, diarrhea, nausea, tiredness and belly pain. Mouth sores, vomiting, hair thinning and low blood counts are more common when capecitabine is combined with other chemotherapy. Hand-foot syndrome causes redness, swelling, tingling or pain on the palms and soles, sometimes with blistering or peeling. It typically appears within the first few months and can wear away fingerprints enough to interfere with fingerprint identification. Raised bilirubin (a liver-processed substance in the blood) is common too, but is usually found on blood tests rather than noticed. With capecitabine, the instruction for several side effects is to stop the tablets and call the care team right away, rather than wait for the next appointment. This applies to diarrhea of 4 to 6 more stools a day than usual or any at night, vomiting two or more times in 24 hours, nausea that clearly cuts down how much you can eat, painful mouth sores, and hand-foot changes that are painful. Treatment is usually restarted at the same or a lower dose once symptoms settle, so stopping early protects the course rather than ending it. Also contact the care team right away for a fever of 100.5°F or higher or other signs of infection, signs of dehydration or passing much less urine, yellowing of the skin or eyes, a rash that blisters or peels, or new chest pain, shortness of breath, dizziness or lightheadedness. Heart problems, including heart attack and irregular heart rhythms, are uncommon but more likely in people who already have coronary artery disease; severe chest pain or pressure needs emergency care. Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing, can be a severe allergic reaction: stop the tablets and get emergency care.
Current Xeloda labeling calls for a genetic test for DPYD variants before starting, unless treatment cannot safely wait. People with complete DPD deficiency should generally not take capecitabine, because even standard doses can cause severe or fatal mouth sores, diarrhea, low blood counts and nerve problems early in treatment. People with partial deficiency may also face higher risk and may start at a lower dose. According to the label, partial deficiency affects about 3 to 5 in 100 White people and complete deficiency about 2 in 1,000, and it appears to be more common in Black people. Tests look for specific variants and differ in what they detect, so a normal result does not rule out serious reactions. Warfarin, a blood thinner, is the most important interaction. Capecitabine strengthens warfarin's effect, and serious, sometimes fatal bleeding has occurred. People taking both need more frequent INR checks (the international normalized ratio, a blood test of how long blood takes to clot; a higher number means slower clotting and greater bleeding risk). The effect can appear within days or months of starting and up to a month after stopping capecitabine, and any unusual bleeding should be reported right away. Avoid folic acid and other folate products, including multivitamins that contain them, unless the care team approves, because they can intensify fluorouracil's side effects. Allopurinol, a gout medicine, may make capecitabine less effective and should be avoided. Capecitabine can raise blood levels of phenytoin, an anti-seizure medicine, so those levels need closer checks, and other medicines that can strain the kidneys add to kidney risk. Share a full list of medicines and supplements with the oncology team. Capecitabine can harm a developing baby. Anyone who could become pregnant should use effective contraception during treatment and for 6 months after the last dose, and anyone with a partner who could become pregnant should do so for 3 months after. It may reduce fertility, and breastfeeding should stop during treatment and for 1 week afterward. People who have had a severe allergic reaction to capecitabine or fluorouracil should not take it.
Treatment runs in cycles, with blood tests before each one to check blood counts and kidney and liver function, and regular check-ins about side effects. After colon cancer surgery, treatment is usually limited to eight three-week cycles, about six months; after pancreatic cancer surgery, it is six four-week cycles alongside gemcitabine. For advanced cancer, it usually continues as long as it keeps the cancer under control and side effects remain manageable, with scans to judge whether it is working. Side effects tend to build over the first weeks and months rather than appear on the first day. In trials, diarrhea first appeared at a median of about a month and hand-foot syndrome at a median of about two and a half months. The week off in most schedules gives the gut, skin and blood counts time to recover. Pauses and dose reductions are common and are a normal part of keeping treatment safe. Because the tablets are taken at home, much of the day-to-day monitoring falls to the person taking them. Knowing the exact schedule, which symptoms mean stopping, and how to reach the team after hours makes the biggest practical difference.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Xeloda (Capecitabine), what you've noticed, or ask the community a question.